Skip to main content

Table 1 CDH1 promoter methylation distribution according to clinical variables and immunohistochemical analysis in 71 IDCs.

From: CDH1promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer

Variable CDH1 methylation p value*
  Presence N (%) Absence N (%)  
Age    0,7842
≤50 19 (76%) 6 (24%)  
>50 33 (72%) 13 (28%)  
Lymph nodea    0,5049
≤4 42 (75%) 14 (25%)  
>4 09 (64%) 5 (36%)  
Clinical Stage    0,5268
I 9 (90%) 1 (10%)  
IIA 16 (67%) 8 (33%)  
IIB 17 (68%) 8 (32%)  
IIIA 4 (100%) 0  
IIIB 6(75%) 2 (25%)  
Histologic grade    0,4282
I 2 (50%) 2 (50%)  
II 37 (76%) 12 (24%)  
III 13 (72%) 5 (28%)  
Immunohistochemical    
E-cadherin    0,1496
   negative/reduced expression (0,1+,2+) 46 (77%) 14 (33%)  
   positive (3+) 6 (55%) 5 (45%)  
Her-2    0,4339
   negative (0,1+,2+) 47 (75%) 16 (25%)  
   positive (3+) 5 (63%) 3 (37%)  
p53    1,0000
   negative (0,1+) 42 (72%) 16 (28%)  
   positive (2+,3+) 10 (77%) 3 (23%)  
ER    0,0301
   negative/reduced expression (0,1+,2+) 37 (82%) 8 (18%)  
   positive (3+) 15 (58%) 11(42%)  
PgR    0,3910
   negative/reduced expression (0,1+,2+) 37 (77%) 11 (23%)  
   positive (3+) 15 (65%) 8 (35%)  
Ki-67    0,0565
   ≤25% 27 (64%) 15 (36%)  
   >25% 25 (86%) 4 (14%)  
  1. * – p-value obtained from Fisher's exact test. Bonferroni correction was applied to statistical adjustment of each p-value (statistically significant p < 0,005); a 70 patients contributed data.